- Home
- AYRO vs BFRI Comparison
AYRO vs BFRI Comparison
Compare AYRO & BFRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AYRO
- BFRI
- Stock Information
- Founded
- AYRO 2017
- BFRI 1997
- Country
- AYRO United States
- BFRI United States
- Employees
- AYRO N/A
- BFRI N/A
- Industry
- AYRO Telecommunications Equipment
- BFRI Biotechnology: Pharmaceutical Preparations
- Sector
- AYRO Consumer Discretionary
- BFRI Health Care
- Exchange
- AYRO Nasdaq
- BFRI Nasdaq
- Market Cap
- AYRO 5.8M
- BFRI 6.2M
- IPO Year
- AYRO N/A
- BFRI 2021
- Fundamental
- Price
- AYRO $0.76
- BFRI $0.97
- Analyst Decision
- AYRO
- BFRI Strong Buy
- Analyst Count
- AYRO 0
- BFRI 1
- Target Price
- AYRO N/A
- BFRI $7.00
- AVG Volume (30 Days)
- AYRO 1.5M
- BFRI 1.4M
- Earning Date
- AYRO 11-14-2024
- BFRI 11-13-2024
- Dividend Yield
- AYRO N/A
- BFRI N/A
- EPS Growth
- AYRO N/A
- BFRI N/A
- EPS
- AYRO N/A
- BFRI N/A
- Revenue
- AYRO $221,671.00
- BFRI $35,358,000.00
- Revenue This Year
- AYRO $2,424.87
- BFRI $17.69
- Revenue Next Year
- AYRO N/A
- BFRI $19.71
- P/E Ratio
- AYRO N/A
- BFRI N/A
- Revenue Growth
- AYRO N/A
- BFRI 5.17
- 52 Week Low
- AYRO $0.65
- BFRI $0.61
- 52 Week High
- AYRO $2.10
- BFRI $4.00
- Technical
- Relative Strength Index (RSI)
- AYRO 48.69
- BFRI 48.79
- Support Level
- AYRO $0.65
- BFRI $0.94
- Resistance Level
- AYRO $0.92
- BFRI $1.25
- Average True Range (ATR)
- AYRO 0.08
- BFRI 0.14
- MACD
- AYRO 0.01
- BFRI -0.00
- Stochastic Oscillator
- AYRO 32.42
- BFRI 30.25
About AYRO AYRO Inc.
AYRO Inc design and manufacture compact, sustainable electric vehicles for closed campus mobility, low-speed urban and community transport, local on-demand and last-mile delivery, and government use. It operates as one reportable segment, which is the design, development, manufacturing, and sales of electric vehicles, and operates in the United States.
About BFRI Biofrontera Inc.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. Its licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its licensed product is Ameluz, which is a prescription drug approved for use in combination with the RhodoLED lamp series, for PDT (when used together, Ameluz PDT). including the complementary product BF-RhodoLED, and Xepi.